Arno W R van Kuijk

Summary

Affiliation: Academic Medical Center
Country: The Netherlands

Publications

  1. ncbi Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment
    A W R van Kuijk
    Division of Clinical Immunology and Rheumatology, Academic Medical Center University of Amsterdam, F4 218, PO Box 22700, 1100 DE Amsterdam, The Netherlands
    Ann Rheum Dis 65:1551-7. 2006
  2. ncbi Synovitis in psoriatic arthritis: immunohistochemistry, comparisons with rheumatoid arthritis, and effects of therapy
    Arno W R van Kuijk
    Department of Rheumatology, Jan van Breemen Institute, Amsterdam, The Netherlands
    Curr Rheumatol Rep 13:353-9. 2011
  3. ncbi Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis
    Maarten C Kraan
    Division of Clinical Immunology and Rheumatology F4 218, Academic Medical Center University of Amsterdam, Meibergdreef 9, NL 1105 AZ Amsterdam, The Netherlands
    Arthritis Rheum 46:2776-84. 2002
  4. ncbi Brief report: a phase IIa, randomized, double-blind, placebo-controlled trial of apilimod mesylate, an interleukin-12/interleukin-23 inhibitor, in patients with rheumatoid arthritis
    Sarah Krausz
    University of Amsterdam, Amsterdam, The Netherlands
    Arthritis Rheum 64:1750-5. 2012
  5. ncbi CCR5 blockade in rheumatoid arthritis: a randomised, double-blind, placebo-controlled clinical trial
    Arno W R van Kuijk
    Academic Medical Center University of Amsterdam, The Netherlands
    Ann Rheum Dis 69:2013-6. 2010

Collaborators

Detail Information

Publications5

  1. ncbi Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment
    A W R van Kuijk
    Division of Clinical Immunology and Rheumatology, Academic Medical Center University of Amsterdam, F4 218, PO Box 22700, 1100 DE Amsterdam, The Netherlands
    Ann Rheum Dis 65:1551-7. 2006
    ..The synovial tissue is a primary target of many inflammatory arthropathies, including psoriatic arthritis (PsA). Identification of proinflammatory molecules in the synovium may help to identify potentially therapeutic targets...
  2. ncbi Synovitis in psoriatic arthritis: immunohistochemistry, comparisons with rheumatoid arthritis, and effects of therapy
    Arno W R van Kuijk
    Department of Rheumatology, Jan van Breemen Institute, Amsterdam, The Netherlands
    Curr Rheumatol Rep 13:353-9. 2011
    ..Finally, a model for proof-of-principle study design using serial synovial biopsies is described, which could be used to predict clinical (in)efficacy in early clinical trial design in PsA...
  3. ncbi Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis
    Maarten C Kraan
    Division of Clinical Immunology and Rheumatology F4 218, Academic Medical Center University of Amsterdam, Meibergdreef 9, NL 1105 AZ Amsterdam, The Netherlands
    Arthritis Rheum 46:2776-84. 2002
    ....
  4. ncbi Brief report: a phase IIa, randomized, double-blind, placebo-controlled trial of apilimod mesylate, an interleukin-12/interleukin-23 inhibitor, in patients with rheumatoid arthritis
    Sarah Krausz
    University of Amsterdam, Amsterdam, The Netherlands
    Arthritis Rheum 64:1750-5. 2012
    ..To investigate the safety, tolerability, pharmacokinetics, and efficacy of apilimod mesylate, an oral interleukin-12 (IL-12)/IL-23 inhibitor, in patients with rheumatoid arthritis (RA)...
  5. ncbi CCR5 blockade in rheumatoid arthritis: a randomised, double-blind, placebo-controlled clinical trial
    Arno W R van Kuijk
    Academic Medical Center University of Amsterdam, The Netherlands
    Ann Rheum Dis 69:2013-6. 2010
    ..The rationale for testing CCR5 blockade in patients with RA was supported by the effects of a CCR5 antagonist in collagen-induced arthritis in rhesus monkeys. The effects of CCR5 blockade in patients with active RA were explored...